Literature DB >> 33621268

Prognostic value of future liver remnant LU15 index of 99mTc-galactosyl serum albumin scintigraphy for predicting posthepatectomy liver failure.

Koichi Tomita1, Naokazu Chiba1, Shigeto Ochiai1, Takahiro Gunji1, Kosuke Hikita1, Toshimichi Kobayashi1, Toru Sano1, Yuta Abe2, Kiyoshi Koizumi3, Motohide Shimazu4, Shigeyuki Kawachi1.   

Abstract

There is no gold standard indicator that is currently used to predict posthepatectomy liver failure (PHLF). A novel indicator of liver function, the LU15 index of 99mTc-galactosyl serum albumin (GSA) scintigraphy, refers to the liver uptake ratio over a 15-min interval. We aimed to evaluate the usefulness of the future liver remnant (FLR)-LU15 in predicting PHLF. The clinical data of 102 patients (70 males and 32 females; median age, 70 years) who underwent liver resection between January 2011 and August 2019 were analyzed. The FLR-LU15 was calculated by a fusion of simulated 3-dimensional images and 99mTc-GSA scintigraphy. PHLF was determined according to the definition of the International Study Group of Liver Surgery. The FLR-LU15 was an independent risk factor for PHLF ≥ Grade B according to multivariate analysis, and its value correlated with the PHLF grade. The area under the receiver operating characteristic curve of the FLR-LU15 for PHLF ≥ Grade B was 0.816 (95% confidence interval, 0.704-0.929), which was better than that of other indicators. When the cut-off value of FLR-LU15 was set at 16.7, the sensitivity was 86.7%, specificity was 74.7%, and odds ratio was 19.2 (95% confidence interval, 4.0-90.9), all of which were superior to other indicators. If the cut-off value was 13, the positive predictive value was 57.1%. The FLR-LU15 is a useful predictor of PHLF and may be more reliable than other predictors.

Entities:  

Year:  2021        PMID: 33621268      PMCID: PMC7901779          DOI: 10.1371/journal.pone.0247675

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  30 in total

Review 1.  Usefulness of Tc-99m-GSA scintigraphy for liver surgery.

Authors:  Masaki Kaibori; Sang Kil Ha-Kawa; Minoru Maehara; Morihiko Ishizaki; Kosuke Matsui; Satoshi Sawada; A-Hon Kwon
Journal:  Ann Nucl Med       Date:  2011-07-29       Impact factor: 2.668

2.  Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy.

Authors:  A H Kwon; S K Ha-Kawa; S Uetsuji; T Inoue; Y Matsui; Y Kamiyama
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

3.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Authors:  Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

4.  Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry.

Authors:  Sander Dinant; Wilmar de Graaf; Bart J Verwer; Roelof J Bennink; Krijn P van Lienden; Dirk J Gouma; Arlène K van Vliet; Thomas M van Gulik
Journal:  J Nucl Med       Date:  2007-05       Impact factor: 10.057

5.  Use of technetium 99m diethylenetriamine-pentaacetic acid-galactosyl-human serum albumin liver scintigraphy in the evaluation of preoperative and postoperative hepatic functional reserve for hepatectomy.

Authors:  A H Kwon; S K Ha-Kawa; S Uetsuji; Y Kamiyama; Y Tanaka
Journal:  Surgery       Date:  1995-04       Impact factor: 3.982

6.  Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up.

Authors:  Masato Nagino; Junichi Kamiya; Hideki Nishio; Tomoki Ebata; Toshiyuki Arai; Yuji Nimura
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

Review 7.  Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment.

Authors:  Maartje A J van den Broek; Steven W M Olde Damink; Cornelis H C Dejong; Hauke Lang; Massimo Malagó; Rajiv Jalan; Fuat H Saner
Journal:  Liver Int       Date:  2008-07       Impact factor: 5.828

8.  Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure?

Authors:  Thiery Chapelle; Bart Op De Beeck; Ivan Huyghe; Sven Francque; Ann Driessen; Geert Roeyen; Dirk Ysebaert; Kathleen De Greef
Journal:  HPB (Oxford)       Date:  2016-03-21       Impact factor: 3.647

9.  Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma - The Albumin-Indocyanine Green Evaluation (ALICE) Grade.

Authors:  Takashi Kokudo; Kiyoshi Hasegawa; Katsumi Amikura; Emilie Uldry; Chikara Shirata; Takamune Yamaguchi; Junichi Arita; Junichi Kaneko; Nobuhisa Akamatsu; Yoshihiro Sakamoto; Amane Takahashi; Hirohiko Sakamoto; Masatoshi Makuuchi; Yutaka Matsuyama; Nicolas Demartines; Massimo Malagó; Norihiro Kokudo; Nermin Halkic
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

10.  Predicting hepatic failure with a new diagnostic technique by preoperative liver scintigraphy and computed tomography: a pilot study in 123 patients undergoing liver resection.

Authors:  Naokazu Chiba; Motohide Shimazu; Kiminori Takano; Go Oshima; Koichi Tomita; Toru Sano; Masaaki Okihara; Yosuke Ozawa; Kosuke Hikita; Takahiro Gunji; Yuta Abe; Kiyoshi Koizumi; Shigeyuki Kawachi
Journal:  Patient Saf Surg       Date:  2017-12-18
View more
  1 in total

1.  Cortisol in Peripheral Blood Predicts the Severity and Prognosis in Patients with Liver Failure at 90 Days.

Authors:  Jian Zhang; Junfeng Li; Mei Ding; Yu Chen; Zhongping Duan
Journal:  Risk Manag Healthc Policy       Date:  2021-10-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.